101488-65-7

Basic information

• Product Name: 3-(4-FLUORO-PHENYL)-PROPYLAMINE
• Synonyms: 3-(4-FLUORO-PHENYL)-PROPYLAMINE;3-(4-FLUOROPHENYL)PROPAN-1-AMINE;OTAVA-BB 1038712;3-(4-fluorophenyl)propan-1-amine(SALTDATA: FREE);4-Fluoro-benzenepropanaMine
• CAS NO: 101488-65-7
• Molecular Formula: C₉H₁₂FN
• Molecular Weight: 153.2
• Mol File: 101488-65-7.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 223.4°C at 760 mmHg
• Flash Point: 98.9°C
• Appearance: /
• Density: 1.044g/cm³
• Vapor Pressure: 0.0966mmHg at 25°C
• Refractive Index: 1.511
• PKA: 10.26±0.10(Predicted)
• CAS DataBase Reference: 3-(4-FLUORO-PHENYL)-PROPYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-FLUORO-PHENYL)-PROPYLAMINE(101488-65-7)
• EPA Substance Registry System: 3-(4-FLUORO-PHENYL)-PROPYLAMINE(101488-65-7)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 101488-65-7(Hazardous Substances Data)

Usage

Description

3-(4-FLUORO-PHENYL)-PROPYLAMINE is an organic compound that serves as a crucial intermediate in the synthesis of various pharmaceuticals and chemical compounds. It is characterized by its unique molecular structure, which features a fluorophenyl group and a propylamine functional group, making it a versatile building block in the development of new drugs and materials.

Uses

Used in Pharmaceutical Industry:
3-(4-FLUORO-PHENYL)-PROPYLAMINE is used as a reactant for the synthesis of triazine-based estrogen receptor modulators that display selectivity for estrogen receptor β. These modulators have potential applications in the treatment of various conditions related to estrogen receptor imbalance, such as hormone-dependent cancers and other estrogen-related disorders.
In the synthesis process, 3-(4-FLUORO-PHENYL)-PROPYLAMINE serves as a key component that contributes to the overall structure and activity of the final product. Its unique properties, such as the presence of a fluorine atom and the propylamine group, enable the formation of specific interactions with the target estrogen receptor, leading to the desired selectivity and modulation of its activity. This makes 3-(4-FLUORO-PHENYL)-PROPYLAMINE a valuable compound in the development of novel therapeutic agents for various medical conditions.

InChI:InChI=1/C9H12FN/c10-9-5-3-8(4-6-9)2-1-7-11/h3-6H,1-2,7,11H2

Upstream product

• 642941-68-2 3-(4-(fluoro)phenyl)acrylamide 
• 872214-99-8 tert-butyl 3-(4-fluorophenyl)propylcarbamate 
• 25468-86-4 3-(4'-fluorophenyl)propanenitrile 
• 352-34-1 4-fluoro-1-iodobenzene 
• 459-32-5 4-fluorocinnamic acid 
• 13565-08-7 4-fluorocinnamoyl chloride 
• 24654-48-6 3-(4-fluorophenyl)acrylonitrile 
• 25468-67-1 3-(4-fluorophenyl)propanamide 
• 852660-33-4 1-(para-fluorophenyl)-3-azidopropane 
• 1403029-82-2 3-(4-fluorophenyl)propyl carbamic acid methyl ester 
• 332-42-3 (2-bromoethyl)-4-fluorobenzene 
• 54930-39-1 3-(4-methylphenyl)propanamine 
• 459-32-5 (E)-4-fluorocinnamic acid 
• 459-31-4 3-(4-fluorophenyl)propanoic acid 

Downstream Products

• 465528-50-1 2-{(1-(3-[4-chlorophenyl]propyl)aminocarbonyl)cyclopentylmethyl}-4-methoxybutyric acid tert-butyl ester 
• 931995-48-1 C₁₀H₁₄FNO₂S 
• 852661-50-8 1-(para-fluorophenyl)-3-(acetamido)propane 
• 872214-99-8 tert-butyl 3-(4-fluorophenyl)propylcarbamate 
• 852660-34-5 (1R,2S)-[2-({[3-(4-fluoro-phenyl)-propyl]amino}-methyl)-cyclohexyl]-carbamic acid benzyl ester 
• 928940-13-0 C₁₆H₁₅FINO 
• 1355153-66-0 C₄₂H₃₅FN₄O₂ 
• 1426152-75-1 C₁₆H₁₅FN₄OS 
• 1418283-50-7 N-[3-(4-fluorophenyl)propyl]-2-(2,4-dichlorophenoxy)propanamide 

Relevant articles and documents

8-Hydroxyquinolin-2(1H)-one analogues as potential β2-agonists: Design, synthesis and activity study

β2-Agonists that bind to plasmalemmal β2-adrenoceptors causing cAMP accumulation are widely used as bronchodilators in chronic respiratory diseases. Here, we designed and synthesized a group of 8-hydroxyquinolin-2(1H)-one analogues and studied their β2-agonistic activities with a cellular cAMP assay. Compounds B05 and C08 were identified as potent (EC50 2-agonists among the compounds tested. They behaved as partial β2-agonists in non-overexpressed HEK293 cells, and possessed rapid smooth muscle relaxant actions and long duration of action in isolated guinea pig tracheal strip preparations. In summary, B05 and C08 are β2-agonists with potential applicability in chronic respiratory diseases.

Transition-metal-free Intramolecular C-H amination of sulfamate esters and: N -alkylsulfamides

The transition-metal-free intramolecular C-H amination of sulfamate esters using iodine oxidants, tert-butyl hypoiodite (t-BuOI) and N-iodosuccinimide (NIS) is reported. A method using NIS was also successfully applied to the oxidative cyclization of N-alkylsulfamides.

Synthesis of Potent and Selective Inhibitors of Aldo-Keto Reductase 1B10 and Their Efficacy against Proliferation, Metastasis, and Cisplatin Resistance of Lung Cancer Cells

Aldo-keto reductase 1B10 (AKR1B10) is overexpressed in several extraintestinal cancers, particularly in non-small-cell lung cancer, where AKR1B10 is a potential diagnostic marker and therapeutic target. Selective AKR1B10 inhibitors are required because compounds should not inhibit the highly related aldose reductase that is involved in monosaccharide and prostaglandin metabolism. Currently, 7-hydroxy-2-(4-methoxyphenylimino)-2H-chromene-3-carboxylic acid benzylamide (HMPC) is known to be the most potent competitive inhibitor of AKR1B10, but it is nonselective. In this study, derivatives of HMPC were synthesized by removing the 4-methoxyphenylimino moiety and replacing the benzylamide with phenylpropylamide. Among them, 4c and 4e showed higher AKR1B10 inhibitory potency (IC50 4.2 and 3.5 nM, respectively) and selectivity than HMPC. The treatments with the two compounds significantly suppressed not only migration, proliferation, and metastasis of lung cancer A549 cells but also metastatic and invasive potentials of cisplatin-resistant A549 cells.